Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
Novavax (NVAX) Stock Price & Analysis
8,816 Followers
NVAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.53 - $13.97
Previous Close$13.11
Volume40.53M
Average Volume (3M)11.38M
Market Cap
$1.79B
Enterprise Value$1.50B
Total Cash (Recent Filing)$568.50M
Total Debt (Recent Filing)$229.08M
Price to Earnings (P/E)-4.1
Beta2.22
Next Earnings
Aug 06, 2024EPS Estimate
$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.18
Shares Outstanding140,403,554
10 Day Avg. Volume32,920,929
30 Day Avg. Volume11,378,391
Standard Deviation0.41
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-1.47
Price to Sales (P/S)1.87
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.53
Enterprise Value/Gross Profit2.35
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$11.75Price Target Upside-7.92% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Novavax News
Bulls Say, Bears Say
Bulls Say
Financial RestructuringFinancially stronger going forward, with progress towards becoming a leaner and financially strong organization.
Market StrategyStrategic prioritization of key ex-US markets, including U.K. commercial market, resulting in delivery of ~$1B APAs through 2026.
Product DevelopmentNovavax' COVID-19 vaccine elicits broad and long-lived immune responses with a favorable reactogenicity profile.
Bears Say
Earnings4Q23 Top/Bottomline Miss, Lowered 1Q Guide Not a Huge Surprise
Market PositionContinuing to command a fringe share of the shrinking C-19 market
Product ChallengesMulti-dose format of Novavax vaccine could lead to pharmacy stock delays or avoidance, potentially resulting in inventory write-downs
---
Ownership Overview
16.96% Insiders
13.80% Mutual Funds
26.35% Other Institutional Investors
42.89% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $3.53 and its highest was $13.97 in the past 12 months.
What is Novavax’s market cap?
Currently, no data Available
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 06, 2024 which is in 84 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 10, 2024. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.064 by $0.014.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Overvalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is $0.2.
How many shares outstanding does Novavax have?
Novavax has 140,403,550 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.064. Following the earnings report the stock price went up 98.658%.
Which hedge fund is a major shareholder of Novavax?
Among the largest hedge funds holding Novavax’s share is Coatue Management, LLC. It holds Novavax’s shares valued at 7M.
---
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.75 (-7.92% Downside)
$11.75 (-7.92% Downside)
Blogger Sentiment
Bullish
NVAX Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.1%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
55.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.26%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
---
NVAX Company Deck
---
NVAX Earnings Call
Q1 2024
0:00 / 0:00
---
NVAX Stock 12 Month Forecast
Average Price Target
$11.75
▼(-7.92% Downside)
Technical Analysis
Best Analysts Covering NVAX
1 Year
1 Year Success Rate
19/35 ratings generated profit
1 Year Average Return
+156.69%
reiterated a buy rating 5 days ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 54.29% of your transactions generating a profit, with an average return of +156.69% per trade.
---